Q2 results, new Ethics & Compliance Head and new Statutory Auditors approved by board
GSK Pharmaceuticals appointed Mr. Sandeep Seth as Head - Ethics & Compliance effective 3 November 2026.
By ScoutQuest · · 2 min read
- Total comprehensive income (Q2 FY27)
- Rs. 33588 lakhs vs Rs. 25749 lakhs in the corresponding quarter
- EPS after exceptional items
- Basic and diluted EPS Rs. 19.83 for the quarter and Rs. 33.83 for the six months
- Other income - tax refund interest
- interest on Income Tax refund of Rs. 4209 lakhs
Three decisions from one board meeting
GlaxoSmithKline Pharmaceuticals' board met on 3 November 2026 and approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, a senior management appointment and a change of statutory auditors.
New Head - Ethics & Compliance
- Mr. Sandeep Seth has been appointed as Head - Ethics & Compliance with effect from 3 November 2026.
- He brings more than 20 years of experience in ethics, compliance and governance across the pharmaceutical, consumer healthcare and health insurance sectors.
- Before joining the company he was Head of Ethics & Business Integrity for Opella, supporting markets across India, Africa, the Middle East and Turkey, and has held compliance leadership roles with Pfizer, MSD Pharma and Max Bupa Health.
- He is a qualified lawyer, a member of the Institute of Company Secretaries of India, a Certified Compliance Professional and a Certified Fraud Examiner, with degrees in Commerce and Law from Delhi University.
- In his new role he will be part of the APAC Compliance leadership team and the India Leadership Team.
New Statutory Auditors
- The board approved M/s Walker Chandiok & Co LLP, Chartered Accountants, as Statutory Auditors for a first term of five consecutive years.
- The term runs from financial year 2027-28 to financial year 2031-32, until the conclusion of the Annual General Meeting to be held in respect of financial year 2031-32.
- The appointment is subject to approval of the Members at the ensuing Annual General Meeting.
- The firm was established in 1935, has its registered office in New Delhi with nineteen other offices across major cities in India, and has ninety-nine partners.
Financial results
- Total comprehensive income for the quarter ended 30 September 2026 was Rs. 33588 lakhs, against Rs. 25749 lakhs in the corresponding quarter.
- Basic and diluted EPS after exceptional items was Rs. 19.83 for the quarter and Rs. 33.83 for the six months ended 30 September 2026.
- Other income for the quarter and six months ended 30 September 2026 includes interest on Income Tax refund of Rs. 4209 lakhs; other income for the six months also includes Rs. 1800 lakhs on account of dividend from the wholly owned subsidiary, Biddle Sawyer Limited.
- Paid-up equity share capital is Rs. 16941 lakhs.
- The company has only one reportable segment, Pharmaceuticals, so no separate segment disclosures have been made.
What a retail reader can take away
- The management change is an appointment to a senior compliance role, effective 3 November 2026.
- The auditor appointment is for a defined first term and is subject to shareholder approval at the coming Annual General Meeting.
- The results were reviewed by the Audit Committee and approved by the Board, and the statutory auditors carried out a limited review of the standalone results.
- Interest on Income Tax refund and dividend from the wholly owned subsidiary sit within other income for the period, separate from sales.
Also from GlaxoSmithKline Pharmaceuticals
GSK India to foray into haemato-oncology with BLENREP launch; adds Calpol 500 and Eltroxin line extensions in Q2 FY2027
3 Nov 2026
Board approves Q2 results, new Ethics & Compliance Head and Walker Chandiok as statutory auditors
3 Nov 2026
GSK Pharmaceuticals schedules digital group investors/analysts meet on 4 November 2026
28 Oct 2026
More numbers
- Basic and diluted EPS after exceptional items, quarter ended 30.09.202619.83
- Basic and diluted EPS after exceptional items, six months ended 30.09.202633.83
- Total comprehensive income, quarter ended 30.09.202633588 (Rs. in Lakhs)
- Total comprehensive income, quarter ended 30.09.202525749 (Rs. in Lakhs)
- Paid-up equity share capital16941 (Rs. in Lakhs)
- Interest on Income Tax refund included in other incomeRs. 4209 lakhs
- Dividend from wholly owned subsidiary Biddle Sawyer LimitedRs. 1800 lakhs
- First term of Statutory Auditors5 (five) years
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.